# Diabetes Research Hub — Daily Iteration Report

**Date:** 2026-06-26 (Friday)
**Agent:** Automated research iteration (state-aware)
**State file:** `Analysis/Results/agent_state.json` (backup: `agent_state.json.bak_2026-06-26`)

## State snapshot at load
- **Papers:** 285 total — 272 VETTED, 13 FLAGGED (all off-topic, correctly excluded), **0 unvetted backlog**.
- **Paths:** 57 in `.paths`, 56 in `.validated_paths`.
- **Gaps:** 15.
- **Work queue:** 23 items. Top item remains **P1 git push — USER-BLOCKED** (see below). Most `audit_gap` / `search_pubmed` items are future-dated (Jul/Aug/Sep), not yet due.
- Not Monday → weekly PubMed sweep (Step 2) intentionally skipped.

## Work completed

### 1. Path validation ×2 (the two stalest flagged in the queue)

**TXNIP_NLRP3_beta_cell_DKD → REAFFIRMED PARTIALLY_VALIDATED**
Web re-validation found a confirming 2025 systematic review (PMC12206412, *NLRP3 Inflammasome-Mediated Pyroptosis in Diabetic Nephropathy: Pathogenic Mechanisms and Therapeutic Targets*) consolidating the TXNIP→NLRP3→pyroptosis axis in renal cells, plus the canagliflozin TXNIP/NLRP3 podocyte data (10.1007/s10753-025-02258-9) keeping the axis drug-tractable. Cross-tissue mechanistic convergence (beta-cell pyroptosis + DKD) is strong, but **clinical translation remains unproven — no human RCT/meta-analysis on TXNIP/NLRP3 endpoints**. Clinical confidence stays NONE.

**Treg_expansion -> T1D → REAFFIRMED PARTIALLY_VALIDATED**
No new efficacy-powered RCT since the 2026-06-16 check. T-Rex phase 2 (Sci Transl Med 2024; PMID 38718135): single-dose expanded polyclonal Tregs were SAFE but did **not** preserve C-peptide in new-onset pediatric T1D. The ld-IL-2 paradoxical dissociation persists (Treg expansion + HbA1c signal without consistent C-peptide preservation, vs immunotherapy preserving C-peptide without HbA1c benefit). Target engagement robust in humans; durable clinical beta-cell preservation from Treg expansion alone remains unproven. Capped at PARTIALLY until an efficacy-powered RCT reads out.

### 2. Credibility sweep — CLEAN
- No fabricated PMIDs (none > 42,000,000).
- No "zero SAEs" / "zero rejection" language in any script.
- 3 `achieves` hits all legitimate: TTP399 tissue-selectivity mechanism, LADA diagnostic cost-effectiveness, ML macro-AUC.
- `curative` appears only inside the `verify_before_deploy.py` guard regex.

### 3. Pipeline rebuild — 41/41 [OK]
`run_quality_improvements.py` completed all 41 stages successfully, including PubMed PMID verification, within the run window.

## State updates written
- `validated_paths` entries for both paths updated (date, notes, validation_history, +1 confirming ref for TXNIP).
- `last_path_validation_batch` set to 2026-06-26.
- `run_history` appended (now 73 runs).
- `work_queue` `validate_path` item advanced — next batch: `empagliflozin->inflammation` (stalest, 2026-03-20) & `verapamil->T1D` (2026-04-22).
- `last_run` / `last_updated` = 2026-06-26.

## ⚠️ Action required by user — git push (P1, still blocked)
The sandbox **cannot** run git: OneDrive denies `unlink` in the sandbox, so every git command leaves a stale 0-byte `index.lock` and a prior attempt briefly corrupted the index. No git was attempted this run. All output files and state are correct but **local-only**. To sync, run in a PowerShell window inside the OneDrive copy:

```powershell
del .git\index.lock
Get-ChildItem .git\index.* -Exclude index | Remove-Item -Force
git add -A; git commit -m "Daily iteration 2026-06-26: path re-validation x2, pipeline 41/41 OK"; git push
```

## Next run focus
- Validate `empagliflozin->inflammation` & `verapamil->T1D` (stalest PARTIALLY).
- Gap audits begin coming due ~2026-07-02 (Gaps #2/#3/#6 GOLD), #3/#15/#9 around 2026-07-03/07.
- Monday 2026-06-29 → run weekly PubMed sweep (Step 2 topic list).
